Incidence, progression and regression of diabetic retinopathy in a northeastern Chinese population. 2022

Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.

OBJECTIVE To determine the incidence, progression and regression of diabetic retinopathy (DR), with corresponding risk factors, in a northeastern Chinese population of patients with type 2 diabetes. METHODS Among 2006 patients who completed baseline examinations in 2012-2013 and underwent re-examination after a mean interval of 21.2 months, 1392 patients with gradable fundus photographs for both baseline and follow-up examinations were included. Incidence was defined as new development of any DR among patients without DR at baseline. An increase of ≥2 scales (concatenating Early Treatment Diabetic Retinopathy Study levels of both eyes) in eyes with DR at baseline was defined as progression, while a reduction of ≥2 scales was defined as regression. RESULTS The age- and sex-standardised incidence, progression and regression were 5.8% (95% CI 4.7% to 6.9%), 26.8% (95% CI 24.8% to 28.8%) and 10.0% (95% CI 8.6% to 11.3%), respectively. In addition to poor blood glucose control, wider central retinal venular equivalent was associated with both incidence (relative risk (RR) 2.17, 95% CI 1.09 to 4.32, for ≥250 µm vs <210 µm) and progression (RR 2.00, 95% CI 1.02 to 3.96, for ≥250 µm vs <210 µm). Patients without insulin therapy (RR 0.64, 95% CI 0.43 to 0.97) and patients with wider central retinal arteriolar equivalent (RR 1.14, 95% CI 1.02 to 1.26, per 10 µm increase) were likely to exhibit DR regression. CONCLUSIONS We determined the incidence, progression and regression of DR among northeastern Chinese patients with type 2 diabetes. Retinal vessel diameters, in addition to blood glucose level, influence the natural evolution of DR.

UI MeSH Term Description Entries

Related Publications

Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
November 2011, Clinical & experimental optometry,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
June 1962, Proceedings of the Royal Society of Medicine,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
January 1999, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
January 2005, Cirugia y cirujanos,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
February 2019, The lancet. Diabetes & endocrinology,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
January 2009, Journal of diabetes and its complications,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
January 2009, Journal of diabetes and its complications,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
August 2012, Diabetes care,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
June 2005, Nihon rinsho. Japanese journal of clinical medicine,
Zhong Lin, and Liang Wen, and Yu Wang, and Dong Li, and Gang Zhai, and Nived Moonasar, and Fenghua Wang, and Yuanbo Liang
January 1994, Ophthalmology,
Copied contents to your clipboard!